GSK (GSK) Stock Forecast & Price Target

GBX 1,334 +0.50 (+0.04%)

(As of 10:09 AM ET)

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 7 Analyst Ratings

Sell
1

Hold
1

Buy
5

Based on 7 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, 1 has given a hold rating, and 5 have given a buy rating for GSK.

Consensus Price Target

GBX 1,805.83

According to the 7 analysts' twelve-month price targets for GSK, the average price target is GBX 1,805.83. The highest price target for GSK is GBX 2,100, while the lowest price target for GSK is GBX 1,600. The average price target represents a forecasted upside of 35.37% from the current price of GBX 1,334.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

GSK Analyst Ratings Over Time

Type	Current Forecast 12/19/23 to 12/18/24	1 Month Ago 11/19/23 to 11/18/24	3 Months Ago 9/20/23 to 9/19/24	1 Year Ago 12/19/22 to 12/19/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	GBX 1,805.83	GBX 1,842.50	GBX 1,805.71	GBX 1,566.36
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

This drone stock is setting up to transform medical supply delivery (Ad)

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Medical Companies
Consensus Rating Score	2.57	2.81
Consensus Rating	Moderate Buy	Moderate Buy
News Sentiment Rating	Neutral News See Recent GSK News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/11/2024	JPMorgan Chase & Co. 3 of 5 stars		Reiterated Rating	Underweight
11/29/2024	Berenberg Bank 2 of 5 stars		Lower Target	Buy	GBX 1,820 ➝ GBX 1,600	+19.27%
9/3/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Reiterated Rating	Buy	GBX 1,850	+11.78%
8/28/2024	Shore Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
7/5/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	GBX 2,120 ➝ GBX 1,900	+24.79%
6/27/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	GBX 2,100	+38.25%
Get the Latest News and Ratings for GSK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
5/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight	GBX 1,725	-1.96%
9/25/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		GBX 1,440 ➝ GBX 1,585	+3.39%
7/17/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		GBX 1,450 ➝ GBX 1,390	+5.22%
3/6/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Keyur Parekh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		GBX 2,000	+38.68%
2/2/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dominic Lunn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	GBX 1,510	+6.16%
2/1/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Leuchten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		GBX 1,245	-13.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:52 AM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 15, 2024. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc has a strong consensus recommendation of "Moderate Buy" from analysts, indicating positive sentiment and potential for stock appreciation.
The current stock price is GBX 1,346.50 ($16.91), which is below the average 12-month price target of GBX 1,842.50 ($23.14), suggesting significant upside potential for investors.
Recent insider transactions show confidence in the company, with insiders purchasing shares, indicating they believe in the company's future performance.
GSK plc is actively involved in innovative research and development, including collaborations for mRNA-based influenza vaccines, positioning it well in the evolving pharmaceutical landscape.
The company has a diverse product portfolio, including vaccines and specialty medicines, which can help mitigate risks associated with reliance on a single product line.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

The company has a high debt-to-equity ratio of 123.04, which may indicate financial risk and could affect its ability to invest in growth opportunities.
GSK plc's PE ratio is extremely high at 1,172.57, suggesting that the stock may be overvalued relative to its earnings, which could deter value-focused investors.
Recent stock performance has shown volatility, with a 1-year low of GBX 1,282.50 ($16.11), indicating potential instability in the market.
One analyst has issued a sell rating, which could signal caution among some investors regarding the company's short-term prospects.
The company operates in a highly competitive industry, which may pose challenges in maintaining market share and profitability against rivals.

GSK Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 1,805.83, with a high forecast of GBX 2,100 and a low forecast of GBX 1,600.
: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There is currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GSK shares.
: According to analysts, GSK's stock has a predicted upside of 35.37% based on their 12-month stock forecasts.
: GSK has been rated by research analysts at Berenberg Bank, and JPMorgan Chase & Co. in the past 90 days.
: Analysts like GSK less than other "medical" companies. The consensus rating score for GSK is 2.57 while the average consensus rating score for "medical" companies is 2.81. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

2025’s #1 Trump Trade (Ad)

All the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies Set to See Enormous Profit Potential.

Details Here.

This page (LON:GSK) was last updated on 12/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target